Abstract P2-05-18: Molecular effects of short pre-operative endocrine therapy in hormone receptor-positive and HER2-negative early breast cancer
Raquel Gómez Bravo(Breast Cancer Research Foundation), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Valeria Sirenko(Breast Cancer Research Foundation), María Rey, Angela Aguirre, Eva Ciruelos, Oleguer Castillo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Meritxell Bellet(Vall d'Hebron Hospital Universitari), Blanca González‐Farré(Hospital Clínic de Barcelona), Tomás Pascual(Breast Cancer Research Foundation), Jordi Canes, Benjamín Walbaum, Paula Blasco(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Olga Martínez‐Sáez(Breast Cancer Research Foundation), Isabel García-Fructuoso(Breast Cancer Research Foundation), Esther Sanfeliu(Hospital Clínic de Barcelona), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Aleix Prat(Hospital Clínic de Barcelona), Elia Seguí, Francesco Schettini(Breast Cancer Research Foundation), Patricia Galván(Vall d'Hebron Hospital Universitari), María Vidal(Inserm), Adela Rodríguez Hernandez, Bárbara Adamo(Hospital Clínic de Barcelona)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
Non-coding recurrent mutations in chronic lymphocytic leukaemia
|Nature|2015|851